Alert detail
LCD L38303: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — CGS
What changed
New genomic classifier coverage supports compliance with updated rates for prostate cancer.
Who’s affected: Oncology billing teams · Effective: March 19, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 3 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.